Oliver Sachgau, a young university graduate living with juvenile arthritis, shared his medication treatment journey with the Globe and Mail this week. He was diagnosed with juvenile arthritis at the young age of 14. Throughout his high school and university years, he kept his arthritis symptom-free by taking the biologics Enbrel, which costs $1,800 a month and was thankfully covered under his family’s insurance plan. When he graduated from university, he was no longer covered under his family’s health plan.
In the article, he said: “I’m not a unique case. Enbrel is part of a class of medication called biologics. For those who take them, biologics can perform miracles. But their high cost, which is rarely mitigated by medical coverage, has created a unique situation for thousands of Canadians who want, but can’t have, their life-changing medication.” The medication cost Canada’s public health plans more than half a billion dollars in 2013, for about 30,000 beneficiaries. Continue reading →
Do you have rheumatoid arthritis and have you recently been recommended to START or SWITCH biologic medications?
Researchers at Arthritis Research Canada would like YOU to try the latest online tool to help make your treatment decisions.
We are looking for people with rheumatoid arthritis across Canada to try a new online tool that helps to make decisions about using biologic medications.
If you have been recommended to consider starting or switching biologic medications, we invite you to participate in this study. You may be eligible if you:
Have rheumatoid arthritis
See a rheumatologist
You are considering or reconsidering starting or switching biologics
Have a valid email and internet access
We are more than halfway there! We now have 28 participants who have completed the study. Please help us reach our recruitment target of 55 participants.
The study will take about two hours to complete over a span of four to six weeks, and can be completed remotely. Any information you provide will be completely confidential. An honorarium will be provided for your time.
If you would like more information, please contact Jasmina Memetovic, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email firstname.lastname@example.org.
The Food and Drug Administration (FDA) has proposed new naming policies for the distinct naming of biosimilars and biologics for rheumatoid arthritis treatment. The new draft guidance is called Nonproprietary Naming of Biological Products: Guidance for Industry and is available to view here.
Under the new policies, which will be designated and enforced by the FDA, separate and distinctive names will be required when it comes to biosimilars and biologic drugs. This will ensure that pharmaceutical companies are following regulations and will remain compliant when it comes to the naming and marketing of biosimilar medications. Continue reading →
Cheryl Koehn, President of Arthritis Consumer Experts, will be presenting in a free webinar on subsequent entry biologics today from 7pm-8pm EST. The webinar is hosted by the Canadian Breast Cancer Network and is the first webinar of 2015 on Subsequent Entry Biologics (SEBs) and how these drugs impact breast cancer treatment.
The network is hosting the webinar in anticipation of SEBs being introduced into breast cancer treatment in about five years when Herceptin comes off patent. Because SEBs have been part of the arthritis community for a number of years now, Cheryl Koehn will explain how the arthritis community has dealt with SEBs and what the Canadian Breast Cancer Network can expect once SEBs for breast cancer enter the marketplace.
Below are the learning outcomes of the webinar:
What are Subsequent Entry Biologics, or SEBs?
Why should you care about SEBs?
What breast cancer specific biologics will be affected?
How did the arthritis community prepare for their arrival into the marketplace?
What can you do to stay abreast of SEB developments in breast cancer?
How to register:
To register for this FREE webinar, please CLICK HERE.
*Once you’ve registered, you should receive a confirmation email within 30 minutes. If you do not receive a confirmation email, please contact Rebecca at email@example.com.
Content for this webinar was made possible through an unrestricted grant from Hoffmann-La Roche Limited.
(Vancouver, BC) — In its eighth annual JointHealth™ Arthritis Medications Report Card, Arthritis Consumer Experts (ACE) reports that, depending on where they live, Canadians living with an autoimmune arthritis may have fewer treatment options or have to “jump through more hoops” to qualify for reimbursement for the medication prescribed for them by their rheumatologist.
“ACE continues to fight for the rights of people with arthritis, which includes our leadership on timely and equitable reimbursement access to arthritis medications on public and private drug formularies. Studies have found that increases in medication treatment costs for rheumatoid arthritis over the last decade are associated with lower hospitalization rates, better functional status and a lower incidence of work disability,” said Cheryl Koehn, Founder and President of Arthritis Consumer Experts.